Novel Advances in Modifying BMPR2 Signaling in PAH

• Published in: Genes Vol. 12; no. 1; p. 8
• Main Authors: Dannewitz Prosseda, Svenja, Ali, Md Khadem, Spiekerkoetter, Edda
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI 23.12.2020
• Subjects: Review; signaling; bone morphogenetic protein receptor 2; PAH; pulmonary hypertension; miRNA; clinical trials; repurposed drugs; pharmaceuticals
• ISSN: 2073-4425; 2073-4425
• DOI: 10.3390/genes12010008

Pulmonary Arterial Hypertension (PAH) is a disease of the pulmonary arteries, that is characterized by progressive narrowing of the pulmonary arterial lumen and increased pulmonary vascular resistance, ultimately leading to right ventricular dysfunction, heart failure and premature death. Current treatments mainly target pulmonary vasodilation and leave the progressive vascular remodeling unchecked resulting in persistent high morbidity and mortality in PAH even with treatment. Therefore, novel therapeutic strategies are urgently needed. Loss of function mutations of the Bone Morphogenetic Protein Receptor 2 (BMPR2) are the most common genetic factor in hereditary forms of PAH, suggesting that the BMPR2 pathway is fundamentally important in the pathogenesis. Dysfunctional BMPR2 signaling recapitulates the cellular abnormalities in PAH as well as the pathobiology in experimental pulmonary hypertension (PH). Approaches to restore BMPR2 signaling by increasing the expression of BMPR2 or its downstream signaling targets are currently actively explored as novel ways to prevent and improve experimental PH as well as PAH in patients. Here, we summarize existing as well as novel potential treatment strategies for PAH that activate the BMPR2 receptor pharmaceutically or genetically, increase the receptor availability at the cell surface, or reconstitute downstream BMPR2 signaling.